Company Profiles

driven by the PitchBook Platform

NGM Biopharmaceuticals

Description

Operator of a bio pharmaceutical company with a drug discovery platform for the treatment of diabetes and obesity. The company develops bio-therapeutics to identify and validate targets that impact the underlying etiology of metabolic, cardio-metabolic and liver diseases as well as focuses on elucidating the biology of hormones, cell receptors and associated ligands.

2008

Founded

PRIVATE

Status

51-200

Employees

Series E

Latest Deal Type

$200M

Latest Deal Amount

$390M

Total Amount Raised

Description

Operator of a bio pharmaceutical company with a drug discovery platform for the treatment of diabetes and obesity. The company develops bio-therapeutics to identify and validate targets that impact the underlying etiology of metabolic, cardio-metabolic and liver diseases as well as focuses on elucidating the biology of hormones, cell receptors and associated ligands.

Website:

www.ngmbio.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology
Other Pharmaceuticals and Biotechnology

Primary Office

630 Gateway Boulevard South San Francisco, CA 94080United States +1 (650) 243-5555
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore NGM Biopharmaceuticals's full profile, request a free trial.

NGM Biopharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

NGM Biopharmaceuticals Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

NGM Biopharmaceuticals Investors (9)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Individual InvestorAngel (individual)Minority000 0000000 0000
Merck Capital VenturesCorporate Venture CapitalMinority000 0000000 0000
Prospect Venture PartnersVenture CapitalMinority000 0000000 0000
Rho VenturesVenture CapitalMinority000 0000000 0000
Solon Mack CapitalFamily OfficeMinority000 0000000 0000
Individual Investor Angel (individual)
Merck Capital Ventures Corporate Venture Capital
Prospect Venture Partners Venture Capital
Rho Ventures Venture Capital
Solon Mack Capital Family Office

NGM Biopharmaceuticals Executive Team (19)

NameTitleBoard
Seat
Contact
Info
William Rieflin JDChief Executive Officer & Board Member
Jin-Long Chen Ph.DFounder, President, Chief Scientific Officer & Board Member
Jeff JonkerPresident
David WoodhouseChief Financial Officer
Aetna Trombley Ph.DVice President, Business Development & Chief Operating Officer
William Rieflin JD Chief Executive Officer & Board Member
Jin-Long Chen Ph.D Founder, President, Chief Scientific Officer & Board Member
Jeff Jonker President
David Woodhouse Chief Financial Officer
Aetna Trombley Ph.D Vice President, Business Development & Chief Operating Officer

NGM Biopharmaceuticals Board Members (8)

NameRepresentingRoleSinceContact
Info
Arthur Levinson Ph.DSelfBoard Member000 0000
David Goeddel Ph.DThe Column GroupManaging Partner000 0000
David Schnell MDProspect Venture PartnersCo-Founder, Partner & Managing Director000 0000
Jin-Long Chen Ph.DNGM BiopharmaceuticalsFounder, President, Chief Scientific Officer & Board Member000 0000
Mark LeschlyRho VenturesManaging Partner000 0000
Arthur Levinson Ph.D Board Member Self
David Goeddel Ph.D Managing Partner The Column Group
David Schnell MD Co-Founder, Partner & Managing Director Prospect Venture Partners
Jin-Long Chen Ph.D Founder, President, Chief Scientific Officer & Board Member NGM Biopharmaceuticals
Mark Leschly Managing Partner Rho Ventures
Request full access to PitchBook